Analysis of clinicopathologic factors in malignant mixed Mullerian tumors of the uterine corpus

被引:43
作者
Inthasorn, P
Carter, J
Valmadre, S
Beale, P
Russell, P
Dalrymple, C
机构
[1] Royal Prince Alfred Hosp, Sydney Canc Ctr, Sydney Gynaecol Oncol Grp, Camperdown, NSW 2050, Australia
[2] Univ Sydney, Sydney, NSW 2006, Australia
[3] Siriraj Hosp, Div Gynaecol Oncol, Bangkok, Thailand
[4] Royal Prince Alfred Hosp, Dept Anat Pathol, Camperdown, NSW 2050, Australia
关键词
mixed Mullerian tumor; uterine corpus;
D O I
10.1046/j.1525-1438.2002.01117.x
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The aim of this study was to retrospectively analyze the clinical and pathologic data of a series of patients presenting to our unit with uterine malignant mixed Mullerian tumors (MMMT) to attempt to identify prognostic factors and relate them to survival. Thirty-seven patients diagnosed with MMMT of the uterus from 1988 through 2000 were identified from the gynecological tumor registry. Data was abstracted and analyzed. The effect of a variety of clinical, histopathologic, and surgical variables on recurrence and survival were analyzed by univariate and multivariate analyses. Patients tended to be postmenopausal, overweight, hypertensive, and presented with abnormal bleeding. Preoperatively 28 (76%) were thought to have clinical stage I-II disease. Nine (32%) were upstaged based on surgical data. Five (56%) of these patients were found to have gross extrauterine disease and four (44%) were found subsequently to have microscopic extrauterine disease. Twenty (54%) patients underwent lymph node dissection and positive nodes were found in seven (35%) patients. Nine patients underwent omentectomy and disease was found in three (33%). Peritoneal washings were positive in three of 16 patients (19%). At the completion of primary surgery, 27 (75%) patients had no residual disease. Twelve (44%) of these patients had recurrence of disease. Median disease-free interval prior to first recurrence was 15 months. Median overall survival was 30 months. Log-rank analysis performed on multiple variables, including stage, age, residual disease, and depth of myometrial invasion showed a statistically significant association with overall survival probability. Only stage remained a significant independent variable predictive of overall survival (P = 0.034). We found that stage was an independent prognostic factor for overall survival in patients with uterine MMMT. Age, depth of myometrial invasion, and residual tumor were significant prognostic factors on univariate analysis. These factors may be a guide in order to select a group of high risk patients that may benefit from adjuvant therapy.
引用
收藏
页码:348 / 353
页数:6
相关论文
共 27 条
[1]   Uterine carcinosarcomas: Incidence and trends in management and survival [J].
Arrastia, CD ;
Fruchter, RG ;
Clark, M ;
Maiman, M ;
Remy, JC ;
Macasaet, M ;
Gates, EJ ;
DiMaio, T ;
Marzec, T .
GYNECOLOGIC ONCOLOGY, 1997, 65 (01) :158-163
[2]  
BERCHUCK A, 1988, OBSTET GYNECOL, V71, P845
[3]   Uterine sarcomas: The Curie Institut experience. Prognosis factors and adjuvant treatments [J].
Chauveinc, L ;
Deniaud, E ;
Plancher, C ;
Sastre, X ;
Amsani, F ;
de la Rochefordiere, A ;
Rozemberg, H ;
Clough, KB .
GYNECOLOGIC ONCOLOGY, 1999, 72 (02) :232-237
[4]   The role of whole-pelvic irradiation in the treatment of early-stage uterine carcinosarcoma [J].
Chi, DS ;
Mychalczak, B ;
Saigo, PE ;
Rescigno, J ;
Brown, CL .
GYNECOLOGIC ONCOLOGY, 1997, 65 (03) :493-498
[5]  
DINH TV, 1989, OBSTET GYNECOL, V74, P388
[6]   The impact of adjuvant radiotherapy on carcinosarcoma of the uterus [J].
Gerszten, K ;
Faul, C ;
Kounelis, S ;
Huang, QS ;
Kelley, J ;
Jones, MW .
GYNECOLOGIC ONCOLOGY, 1998, 68 (01) :8-13
[7]   PROGNOSTIC VALUE OF PERITONEAL WASHINGS IN PATIENTS WITH MALIGNANT MIXED MULLERIAN TUMORS OF THE UTERUS [J].
GESZLER, G ;
SZPAK, CA ;
HARRIS, RE ;
CREASMAN, WT ;
BARTER, JF ;
JOHNSTON, WW .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1986, 155 (01) :83-89
[8]   CEREBRAL METASTASIS FROM A MALIGNANT MIXED MULLERIAN TUMOR OF THE UTERUS [J].
IQBAL, JB ;
IRONSIDE, JW .
HISTOPATHOLOGY, 1993, 23 (03) :277-279
[9]  
Iwasa Y, 1998, CANCER-AM CANCER SOC, V82, P512, DOI 10.1002/(SICI)1097-0142(19980201)82:3<512::AID-CNCR13>3.3.CO
[10]  
2-K